BioSpace News Archive

argenx SE announced the presentation of new data from its neuromuscular franchise at the American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting and the Myasthenia Gravis Foundation of America Scientific Session, both being held in Nashville, TN.

POXEL SA announced positive histology results for DESTINY-1, the dose-ranging Phase 2 trial of PXL065 for the treatment of NASH.

POXEL SA announced its financial results for the period ended June 30, 2022 and provided a corporate update.

Poolbeg Pharma announces that further to the Option Agreement announced in December 2021, Poolbeg has signed an exclusive Licence Agreement with University College Dublin through NovaUCD, the University’s knowledge transfer office, for a late preclinical stage vaccine candidate for Melioidosis, a disease for which there is no current approved vaccine available.

EIP Pharma Inc. announced publication of an article in Nature Communications showing translational results from preclinical animal models to an exploratory, placebo-controlled clinical trial of neflamapimod in patients with mild to moderate Dementia with Lewy Bodies.

The clinical-grade, laboratory-developed test for polygenic risk score for coronary artery disease, breast cancer, prostate cancer, Type 2 Diabetes, and Alzheimer’s disease is now available for purchase direct from Allelica.

Adapsyn Bioscience Inc. today announced a strategic collaboration with Evotec SE.

Carmot Therapeutics, Inc. announced today an expansion of its Board of Directors and executive leadership team.

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer’s disease.”

Castle Biosciences, Inc. today provided a proposed framework of the Company’s diagnostic gene expression profile (GEP) tests, MyPath® Melanoma and DiffDx®-Melanoma, for use in clinical practice to help achieve personalized management and treatment plans.